alexa Peginterferon and ribavirin in HCV: improvement of sustained viral response.


Journal of Addiction Research & Therapy

Author(s): Ferenci P

Abstract Share this page

Abstract Peginterferon alfa in combination with ribavirin is and will remain for the next years the current standard for treatment of chronic hepatitis C. The new antivirals currently investigated in phase II of III trials may augment the overall response rates but require peginterferon/ribavirin as backbone. The cure rate of peginterferon/ribavirin treatment can be improved by better education of treating physicians to identify and treat conditions which negatively influence the final outcome of therapy. Specific focus is the prevention and/or early treatment of common side effects of therapy including anaemia, cytopenia and depression. In selected patients increasing the dose of peginterferon and/or ribavirin may augment response rates. Measuring the viral response at various time points during treatment allows individualization of treatment duration. Treatment duration may be shortened in patients with undetectable HCV-RNA after 4 weeks of therapy, on the other hand slow virologic responders may benefit from prolonged treatment. This article was published in Best Pract Res Clin Gastroenterol and referenced in Journal of Addiction Research & Therapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version